NCT Number: NCT05530408
The goal of this project is to establish a registry and biorepository of images and biological samples from subjects undergoing novel pulmonary imaging methods to be used for future research aimed toward identifying clinical applications of imaging methods and toward understanding the physiological significance of imaging biomarkers. This registry and biorepository will accelerate the development of these imaging techniques and may lead toward future clinical adoption of quantitative pulmonary imaging.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Kansas City, Kansas, 66160, United States
Location status: Recruiting
Adam M Ruff, BS
CONTACT
Chase M Hall, MD
SUB_INVESTIGATOR
Cristal Monge
CONTACT
Jiwoong Choi, PhD
SUB_INVESTIGATOR
Peter J Niedbalski, PhD
PRINCIPAL_INVESTIGATOR
Imaging is increasingly used for the non-invasive assessment of pulmonary health. Alongside this increased usage, there is enhanced interest in quantitative imaging methods that provide robust, repeatable, and objective measures of lung structure and function. At the forefront of this effort is quantitative computed tomography (qCT). CT imaging is the gold standard for high-resolution imaging of pulmonary structure, and the underlying physics of CT imaging is highly amenable to quantitative analysis.
In addition to qCT, MRI is garnering increased interest as a modality for pulmonary imaging. Like CT, MRI is non-invasive, and it has the additional advantage of being ionizing radiation-free, making it more suitable for repeat imaging and for use in pediatric patients. Traditionally, MRI was not often used for lung imaging due to several difficulties regarding the acquisition of quality images in the lungs. However, recent advances to pulmonary MRI methods have enabled the acquisition of high-quality images of pulmonary structure and function. These advances include the use of ultra-short and zero echo time (UTE and ZTE, respectively) MRI methods, as well as the use of gaseous contrast agents such as hyperpolarized 129Xe.
Despite these advances in qCT and MRI methods, the clinical applications for these imaging techniques are often unclear. Moreover, as new techniques, many of the imaging biomarkers in use have been independently developed by multiple sites and thus require standardization. As such, there is an urgent need both to standardize imaging/analysis techniques and to determine optimal clinical applications for these novel quantitative imaging methods.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: From Enrollment to 3 Months
Collect relevant medical history (including demographic information, diagnoses, medical tests, smoking history), for patients participating in pulmonary imaging research.
Time frame: From Enrollment to 3 Months
Establish a collection of biospecimens from imaging subjects to foster an improved understanding of the physiological significance of imaging biomarkers.
Time frame: From Enrollment to 6 Months
Correlate imaging biomarkers with biospecimens and physiological/vital signs data.
Time frame: From Enrollment to 12 Months
Provide images and biospecimens to researchers working to develop analysis methods for pulmonary CT and MRI. Separate IRB approval, alongside appropriate data and/or materials transfer agreements will be needed for these studies.
Contact information is provided by the study sponsor or research team.
Adam M Ruff, BS
CONTACT
Cristal Monge
CONTACT
University of Kansas Medical Center
Other
Acronym: PIBR
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00077909
Infections, Lung Disease
Bethesda, Maryland, United States
View Trial DetailsNCT05153967
Anemia, Anemia, Hemolytic
Washington D.C., District of Columbia, United States
View Trial DetailsNCT01730092
Cardiovascular Diseases, Hypertension
Bethesda, Maryland, United States
View Trial DetailsNCT04645602
Human Papilloma Virus, Lung Diseases
New Haven, Connecticut, United States
View Trial Details